Bio-Techne Corp (TECH)
NEUTRALFundamental
53
Kurs
$72.34
Marktkapitalisierung
$11.27B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$1.21B
Letzte 12 Monate (bis 31.3.2026)
Nettogewinn
$110M
Letzte 12 Monate (bis 31.3.2026)
Freier Cashflow
$257M
Gesamtes Eigenkapital
$1.92B
Gesamtverbindlichkeiten
$639M
Current Ratio
4.49
Zinsdeckungsgrad
15.88
Schulden/EBITDA
1.37
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$40.41
Aktueller Kurs
$72.34
Sicherheitsmarge
-79.0%
Innerer-Wert-Spanne
$26.27 - $54.55
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
104.91
ROE
3.8%
P/B-Verhältnis
5.44
P/FCF
42.04
Bruttomarge
65.0%
ROIC
5.1%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
5.1%
WACC
11.4%
ROIC − WACC
-6.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (15)
- Price CAGR 10.90%
- ROIC 5.1%
- Gross Margin 65.0%
- Debt/Equity ratio
- Operating Margin 12.7%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 10.6%
- Earnings Quality (OCF/NI) 2.69
- Share Dilution -0.3%
- Piotroski F-Score 5/9
Nicht bestanden (11)
- EPS shows upward trend
- EPS CAGR -10.63%
- P/FCF 42.04
- P/B Ratio 5.44
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 5.4%
- Analyst Consensus 41% Buy
- Earnings Surprise avg 0.7%
- Net Margin Trend 9.0% vs 10.9%
Nicht verfügbar (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Kim Kelderman | CEO, President & Director | 57 |
| Mr. William A. Geist | President of Protein Sciences Segment | 56 |
| Dr. Gary J. Latham Ph.D. | VP & CTO | - |
| Mr. David Clair C.F.A. | Vice President of Investor Relations | - |
Prüfungsrisiko
8
Vorstandsrisiko
1
Vergütungsrisiko
10
Aktionärsrechterisiko
1
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for TECH, sourced from Markets Gazette.
- 6/15/2026POSITIVEActivist Investor Ananym Urges Bio-Techne to Consider Selling
Activist investor Ananym Capital Management has acquired a significant stake in Bio-Techne Corp., signaling a potential shift in the company's strategic direction. Ananym is actively urging the Bio-Techne board to initiate a comprehensive strategic review, with a primary focus on exploring a potential sale of the company. This development could lead to a substantial premium for shareholders if a sale materializes, as activist campaigns often aim to unlock shareholder value through such actions. Investors will be closely watching Bio-Techne's response and any subsequent strategic decisions.
- 3/13/2026NEGATIVEIs Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?
A significant wealth management firm has divested its entire stake in Bio-Techne Corporation, a developer of life sciences reagents and diagnostic solutions. While the specific reasons for the liquidation were not disclosed, the complete exit by a major investor raises concerns about potential headwinds or a reassessment of the company's future growth prospects. Investors will be closely watching for any further commentary from the firm or Bio-Techne management to understand the underlying drivers of this substantial sell-off, which could impact short-term sentiment and stock performance.
via Markets Gazette